MedTrace Logo

Dose-Escalation Safety and Pharmacokinetic Study of K305

NCT01304316 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-08-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the pharmacokinetics/pharmacodynamics and safety of a nasal spray containing the anesthetic drug tetracaine in combination with oxymetazoline

Conditions

  • Anesthesia

Interventions

DRUG

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Sponsors & Collaborators

  • Ground Zero Pharmaceuticals

    collaborator INDUSTRY

  • Rho, Inc.

    collaborator INDUSTRY

  • St. Renatus, LLC

    lead INDUSTRY

Principal Investigators

  • Elliot V Hersh, DMD, MS, PhD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304316 on ClinicalTrials.gov